Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Expects Cinacalcet Phase IIIb Trials To Increase Physician Awareness

Executive Summary

Amgen is trying to increase physician awareness of the hyperparathyroidism agent cinacalcet prior to launch by conducting Phase IIIb studies, Exec VP-Global Commercial Operations George Morrow said

You may also be interested in...



Sensipar Hypocalcemia Studies Are Key To Expanded Indication, Amgen Says

Long-term hypocalcemia safety studies will be necessary before Amgen gains approval of an expanded indication for the chronic kidney disease agent Sensipar

Amgen Sensipar Clears FDA: Phosphate Binders Are A Competitive Target

Amgen's chronic kidney disease therapy Sensipar will be available within the next few weeks following FDA's March 8 approval, the company said

Sensipar Hypocalcemia Studies Are Key To Expanded Indication, Amgen Says

Long-term hypocalcemia safety studies will be necessary before Amgen gains approval of an expanded indication for the chronic kidney disease agent Sensipar

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel